A TNFR2 antibody by countering immunosuppression cooperates with HMGN1 and R848 immune stimulants to inhibit murine colon cancer

2021 ◽  
Vol 101 ◽  
pp. 108345
Author(s):  
Mengmeng Jiang ◽  
Jia Liu ◽  
De Yang ◽  
Debra Tross ◽  
Ping Li ◽  
...  
Author(s):  
Khushboo Kourani ◽  
Poonam Jain ◽  
Aviral Kumar ◽  
Ashok Kumar Jangid ◽  
Guruprasadh Swaminathan ◽  
...  

2017 ◽  
Vol 46 (9) ◽  
pp. 3025-3040 ◽  
Author(s):  
Gabriella Tamasi ◽  
Antonello Merlino ◽  
Federica Scaletti ◽  
Petra Heffeter ◽  
Anton A. Legin ◽  
...  

fac-[RuII(CO)3Cl2(MBI)] and -[RuII(CO)3Cl2(DMBI)] are CO-releasing materials able to link histidines of proteins, and the latter showed antitumor effects in murine colon cancer.


2020 ◽  
Vol 8 (2) ◽  
pp. 175 ◽  
Author(s):  
Xuerun Liu ◽  
Luoyang Wang ◽  
Nan Jing ◽  
Guoqiang Jiang ◽  
Zheng Liu

Recent advances have revealed the essential role of gut microbiomes in the therapeutic efficiency of immune checkpoint inhibitors (ICIs). Inspired by biostimulation, a method using nutrients to accelerate the growth of soil microorganisms and the recovery of soil microbial consortia, here we propose a bilberry anthocyanin combo containing chitosan and low molecular citrus pectin (LCP), in which LCP–chitosan is used to encapsulate anthocyanins so to enhance its digestive stability and, moreover, modulate the microbiome more favorable for the PD-L1 blockade treatment. Using murine MC38 colon cancer as a model system, we examined the effects of the combo on modulating the gut microbiome and therapeutic efficiency of PD-L1 blockade treatment. It was shown that bilberry anthocyanins enriched the subdominant species, increased both the concentration and the proportion of butyrate in feces and enhanced intratumoral CD8+ T cell infiltrations. The application of the bilberry anthocyanin combo restored the species diversity of gut microbiome decreased by LCP–chitosan and achieved the best control of tumor growth. These preliminary results indicated unprecedented opportunities of probiotics combo in improving the therapeutic efficiency of immune checkpoint inhibitor through manipulating gut microbiome.


2015 ◽  
Vol 473 (1) ◽  
pp. 7-19 ◽  
Author(s):  
Tiangeng Dong ◽  
Tuo Yi ◽  
Mengxuan Yang ◽  
Shengli Lin ◽  
Wenxiang Li ◽  
...  

This is the first demonstration that α-galactosylceramide (α-Galcer)-loaded tumour cells (tumour–Gal) plus the Toll-like receptor 9 (TLR9) agonist as therapeutic anti-cancer vaccination. This strategy may have broad applicability and lead to development of effective immunotherapy against various human cancers.


2011 ◽  
Vol 58 (110-111) ◽  
Author(s):  
Takashi Shirota ◽  
Hideki Kasuya ◽  
Yasuhiro Kodera ◽  
Yoko Nishikawa ◽  
Toshio Shikano ◽  
...  

2007 ◽  
Vol 12 (1) ◽  
pp. 330-342 ◽  
Author(s):  
Hala Gali-Muhtasib ◽  
Matthias Ocker ◽  
Doerthe Kuester ◽  
Sabine Krueger ◽  
Zeina El-Hajj ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document